معرفی
Alain Hovnanian leads a research team focused on genetic skin diseases, particularly dystrophic epidermolysis bullosa, Netherton syndrome, and Darier disease. His work integrates molecular mechanisms, therapeutic development (gene therapy, protein replacement, and small molecules), and clinical trials. He is affiliated with INSERM, leading studies on gene correction using lentiviral vectors, CRISPR/Cas9, and mesenchymal stem cells. His team also investigates inflammatory pathways (IL-17/IL-36, TSLP) and protease inhibitors for Netherton syndrome. Collaborations include developing KLK5/7 inhibitors and mTOR inhibitors for epidermolysis bullosa. Preclinical models include humanized mice and xenograft systems to test therapies.
Research spans from identifying modifier genes in DEB fibrosis to repurposing drugs like diacerein. His group actively participates in clinical trials such as the EBGene ex vivo gene therapy trial for recessive DEB. Key areas include understanding ER stress in Darier disease and advancing therapies targeting calcium homeostasis.
Team members include postdocs, PhD students (e.g., Mathilde Bonnet des Claustres), and engineers. Ongoing projects address hidradenitis suppurativa, psoriasis, and Olmsted syndrome through exome sequencing and functional studies. Lab focuses on translating molecular insights into treatments, including biotherapies and pharmacological approaches.
